Student Loan Sudden...
Health Care: Drugs
Celgene Corporation (CELG: NASDAQ)
$118.86 -1.38 | -1.15%
06/19/13 - 01:20 PM ET
Portfolios with CELG
- Portfolio NameUser Type
- ContributorStocks Fund Managers Love S...
- ProRenaissance Technologies
- UserQuicksilver55
- Userdennis all star
- Userportfolio 1.1
- UserCraigMcIlquham
- User4 Overvalued Biotechs
- ProRay Dalio - Bridgewater Ass...
- ProBill Miller - Legg Mason Ca...
- ContributorStocks Rising On Unusual Vo...
Latest CELG Headlines from TheStreet
- Celgene Corporation (CELG): Today's Featured Health Care Laggard 04.18.13 | 05:04 pm
- The Next Big Thing In Biotech: Large-Cap Earnings
04.18.13 | 09:04 am - 5 Stocks Pushing The Drugs Industry Downward 04.15.13 | 01:04 pm
- Cramer's 6 Stocks in 60 Seconds: UA ADBE FTNT ACAD CELG RLGY (Update 1) 04.11.13 | 05:04 pm
- Health Care Standout Celgene Corporation (CELG) Making Gains Today 04.11.13 | 05:04 pm
- Celgene Corporation Stock Buy Recommendation Reiterated (CELG) 04.11.13 | 10:04 am
- Celgene Reaches New 52-Week High (CELG) 04.10.13 | 11:04 am
- Market Takes Aim at Historic Highs Once Again 04.10.13 | 09:04 am
- Risk Of A Major Stock Correction Is Growing 04.09.13 | 01:04 pm
- Biotech Multiples Are Soaring But M&A Is Dead 04.08.13 | 12:04 pm
Press Releases for CELG
- Myelodysplastic Syndromes (MDS): An Overview (Graphic: Business Wire) - Business Wire 06.17.13 | 01:06 am
- Celgene Corporation To Webcast At Two Upcoming Investor Conferences And The American Academy Of Dermatology Annual Meeting - Business Wire 02.28.13 | 08:02 am
- Celgene Announces $600 Million Accelerated Share Repurchase Program - Business Wire 02.20.13 | 08:02 am
- Celgene Provides REVLIMID® Regulatory Update - Business Wire 02.11.13 | 07:02 am
- POMALYST(R) Brand Therapy (Photo: Business Wire) - Business Wire 02.08.13 | 03:02 pm
- Celgene Corporation To Webcast At Upcoming Investor Conferences - Business Wire 02.04.13 | 08:02 am
- Celgene Reports Strong Fourth Quarter And Full Year 2012 Operating And Financial Results - Business Wire 01.24.13 | 07:01 am
- The True Effect: Positive Findings - Research Report On Celgene Corporation And Gilead Sciences, Inc. - PR Newswire 01.23.13 | 08:01 am
- ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer - Business Wire 01.22.13 | 06:01 pm
- Celgene Corporation Announces Financial Outlook And Preliminary 2012 Results - Business Wire 01.07.13 | 11:01 am
Partner Headlines for CELG
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks On The Move Table Identifies Emerging Leaders - Investor's Business Daily 04.10.13 | 05:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- Stocks Open Sharply Lower After Employment Report - Investor's Business Daily 04.05.13 | 10:04 am
- Benzinga's Top Upgrades - Benzinga 04.05.13 | 08:04 am
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Top Funds' New Buys: Lumber Liquidators, Celgene - Investor's Business Daily 04.02.13 | 06:04 pm
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
